An interventional study of SELUTION SLR and DES in Coronary Artery Disease, sponsored by M.A. Med Alliance S.A.. Active, not recruiting at 62 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by M.A. Med Alliance S.A. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 365 studies in Coronary Artery Disease with a site in Germany — 46 open to participants now, 71 under way, 3 of them phase 3. Coronary Artery Disease · Germany.
Among the 365 studies in Coronary Artery Disease with a site in Germany, this one is the 19th largest by enrollment of the 248 interventional ones that give a count, is one of 11 that started in 2021, is one of 128 with no phase, reaches primary completion later than 19 of the 70 other live ones, and was the 306th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →46 of the 365 studies in Coronary Artery Disease with a site in Germany are open now. Recruiting first, the newest first:
German Heart Institute · Sites in Germany
Ages 18+
Novartis Pharmaceuticals · Sites in Germany, United States, Australia and 2 more countries
Ages 18–80
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Emory University · Sites in Germany, United States, Serbia
Ages 18+
B. Braun Melsungen AG · Sites in Germany, Switzerland
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
365 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 32 · Phase 3 39 · Phase 4 47
First in 1999; this study’s year is marked. 11 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,326 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 265 across the 248 interventional studies, 550 across the 117 observational. Of the 237 that completed or were terminated, 56 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
171 of 365 have an industry lead sponsor. The 10 most frequent:
M.A. Med Alliance S.A. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
M.A. Med Alliance S.A. has 2 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
14 of the studies in Coronary Artery Disease with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04196712University Hospital, EssenEssen Coronary Artery Disease Registry | 2026-12-30 |
| NCT03820492Insel Gruppe AG, University Hospital BernComparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT | 2026-12-31 |
| NCT05540223Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System | 2027-02 |
| NCT06678490OrbusNeichSupport C Post-Market Registry | 2027-02 |
| NCT06535854Medtronic VascularPrevail Global Study | 2027-02 |
Add all 14 to your calendar (.ics) → With an account.
Among the 365 studies in Coronary Artery Disease with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Prospective Randomized, Multi-centre, International, Open Label, Clinical trial comparing the Selution DEB strategy versus DES strategy.
Randomized, multi-centre, international, open label, clinical trial. Patients meeting eligibility criteria will be randomized 1:1 to treatment of all lesions of the identified trial target vessel(s) with either the SELUTION SLR DEB or DES.
Patients randomized to the SELUTION SLR DEB arm will receive lesion preparation according to the 3rd DCB consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, shockwave, rotational atherectomy or cutting or scoring balloon at the discretion of the operator when necessary to maximize lumen diameter). Patients with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis > 30% or FFR \< 0.8) before or after use of DEB will receive a DES but remain in the SELUTION DEB group (intention to treat analysis).
Patients randomized to the DES arm will receive treatment using any CE-marked DES, as per standard institutional practice. Patients with failure to deliver DES will be first treated by provisional DEB using the SELUTION DEB, and failing that, with any other device deemed appropriate.
Staged procedures are allowed if they are planned less than 45 days after the index procedure and are done according to the initial treatment allocation for all trial target vessels (DEB if DEB arm, DES if DES arm).
The study will test:
All Patients will be followed for clinical outcomes at 30 days, 6 months, 1 2, 3, 4 and 5 years.
Subjects must meet all the following criteria to participate in the trial:
Exclusion Criteria:
Age \< 18 years (or 21 according to countries legal age)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: SELUTION SLR DEB. For patients randomized to the DEB strategy, all target lesions should be treated with DEB after appropriate lesion preparation, but provisional DES implantation is acceptable if the angiographic result is considered insufficient either after lesion preparation of after DEB treatment (poor flow, dissection type C or higher, residual stenosis \> 30%). For bifurcation lesions, when both main and side- branch are considered to require treatment, a DEB should be used for both.
Device: SELUTION SLR
Device: Drug Eluting Stent. For patients randomized to the DES strategy, all target lesions should be treated with DES, but use of a SELUTION SLR™ DEB or any other device is acceptable if a DES cannot be delivered to the target lesion. For bifurcation lesions, if the side-branch requires treatment it should be treated with another DES or with POBA, at the discretion of the operator, but not with a DEB.
Device: DES
Patients randomized to the SELUTION SLR™ DEB arm will receive lesion preparation according to the 3rd DCB consensus (optimal balloon angioplasty with adjunct treatment using high-pressure balloon, shockwave, rotational atherectomy or cutting or scoring balloon at the discretion of the operator when necessary to maximize lumen diameter). Patients with lesions that are then best treated by provisional stenting (flow-limiting dissection, residual stenosis \> 30% or FFR \< 0.8) before or after use of DEB will receive a DES but remain in the SELUTION SLR™ DEB group (intention to treat analysis).
For patients randomized to the DES strategy, all target lesions should be treated with DES, but use of a SELUTION SLR™ DEB or any other device is acceptable if a DES cannot be delivered to the target lesion. For bifurcation lesions, if the side-branch requires treatment it should be treated with another DES or with POBA, at the discretion of the operator, but not with a DEB.
TVF
\- TVF (cardiac death, target-vessel related myocardial infarction (MI) or clinically driven target vessel revascularization (cd-TVR) at 1 year
Time frame: 1 year after treatment
TVF
\- TVF (cardiac death, target-vessel related myocardial infarction (MI) or clinically driven target vessel revascularization (cd-TVR)) at 5 years
Time frame: 5 years after treatment
Death or any MI
Cardiac death, non-cardiac death, or any Myocardial Infarction
Time frame: 30 days after treatment
CD-TVR
Clinically driven - Target Vessel Revascularization
Time frame: 30 days after treatment
TVF
Target Vessel Failure
Time frame: 2, 3, 4, 5 years after treatment
Any revascularization
1. Target lesion revascularization (TLR) - any and clinically driven 2. Target vessel revascularization (TVR) - any and clinically driven 3. A new lesion revascularization in a target vessel 4. Non-Target vessel revascularization
Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment
Myocardial Infarction (MI)
1. Peri-procedural MI 2. Target-vessel MI 3. Non-target-vessel MI 4. MI type (1 to 5) according to the 4th universal definition
Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment
Composite of cardiac death or target vessel MI
Composite of cardiac death or target vessel Myocardial Infarction
Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment
All-cause mortality
* Cardiac mortality * Non-cardiac mortality
Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment
Patient-oriented ARC-2 composite endpoint
1. All-cause mortality 2. Any stroke 3. Any MI (includes non-target vessel territory) 4. Any revascularization
Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment
Site-reported stroke
Site-reported stroke
Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment
Site-reported BARC 3-5 Bleeding
Site-reported BARC (Bleeding Academic Research Consortium ) 3-5 Bleeding
Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment
Cost-effectiveness of DEB vs. DES after 12 months in selected countries
Total costs of materials used during treatment
Time frame: 1, 2, 3, 4 and 5 years after treatment
Cost-effectiveness of DEB vs. DES after 12 months in selected countries
Time of procedure. Total minutes from patient introducer introduction until removal
Time frame: 1, 2, 3, 4 and 5 years after treatment
Cost-effectiveness of DEB vs. DES after 12 months in selected countries
Total hospitalization days per procedure.
Time frame: 1, 2, 3, 4 and 5 years after treatment
Net clinical benefit, a combination of freedom from TVF and/or BARC 3-5 bleeding
Net clinical benefit, a combination of freedom from (Target Vessel Failure) TVF and/or BARC 3-5 bleeding
Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment
Device success
Device success defined as achievement of a final residual diameter stenosis of \< 30% (site-reported), using the assigned device only
Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment
Lesion success
Lesion success defined as achievement of \< 30% residual stenosis (site-reported), using any PCI method
Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment
Procedure success
Procedure success defined as achievement of a final diameter stenosis of \< 30% (site-reported) using any PCI method, without the occurrence of death, MI, or repeat target vessel revascularization during hospital stay
Time frame: 30 days, 6 months, 1, 2, 3, 4 and 5 years after treatment
Plan to share: No
Ran from May 2021 to primary completion in Sep 2025, 52 months.
Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's 52 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
M.A. Med Alliance S.A.